Clinical Trials Browser

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05586061 2025-02-07

RCTS

Phase 2 Active not recruiting

55 enrolled

Gastrointestinal

HER2-positive Gastric Cancer

NCT06239532 2024-11-21

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

Phase 2 Active not recruiting

28 enrolled

Gastrointestinal

Cholangiocarcinoma

NCT05520619 2024-11-18

EC-CRT-002

Phase 2 Active not recruiting

114 enrolled

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT05724329 2024-09-19

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Phase 2 Active not recruiting

24 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

Clinical Trials

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy

HOVON164HL

Tislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial

First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer

Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer

Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer

SACTION01

Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

ACROPOLI

RCTS

HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma

EC-CRT-002

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)